About Orna
Orna is a company based in Cambridge (United States) founded in 2020 by Alexander Wesselhoeft was acquired by Lilly in February 2026. Orna has raised $201 million across 2 funding rounds from investors including Lilly, Novartis and Merck. The company has 113 employees as of December 31, 2022. Orna has completed 1 acquisition, including ReNAgade. Orna offers products and services including oRNA, panCAR, and LNP Delivery. Orna operates in a competitive market with competitors including Dicerna Pharmaceuticals, OliX Pharmaceuticals, Envisagenics, Rznomics and Arcturus Therapeutics, among others.
- Headquarter Cambridge, United States
- Employees 113 as on 31 Dec, 2022
- Founders Alexander Wesselhoeft
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Orna Therapeutics, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$201 M (USD)
in 2 rounds
-
Latest Funding Round
$121 M (USD), Series B
Aug 14, 2022
-
Investors
Lilly
& 10 more
-
Employee Count
113
as on Dec 31, 2022
- Investments & Acquisitions
-
Acquired by
Lilly
(Feb 09, 2026)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Orna
Orna offers a comprehensive portfolio of products and services, including oRNA, panCAR, and LNP Delivery.
Engineered circular RNA for enhanced protein expression in disease treatment.
In vivo system for cancer cell therapy without preconditioning.
Lipid nanoparticles for targeted RNA delivery beyond the liver.
People of Orna
Unlock access to complete
Unlock access to complete
Funding Insights of Orna
Orna has successfully raised a total of $201M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $121 million completed in August 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Orna
Orna has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include Lilly, Novartis and Merck.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Taiho Ventures is focused on investing in global biotech ventures.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Orna
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Orna
Orna has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include ReNAgade.
Investment portfolio details for Orna
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
RNA-based medicines are developed for treating multiple diseases.
|
Locked | Locked | 2021 | Locked |
Complete acquisition details for Orna
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Orna
Detailed financials for Orna
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Orna Comparisons
Peer comparison for Orna
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Orna
Orna operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Dicerna Pharmaceuticals, OliX Pharmaceuticals, Envisagenics, Rznomics and Arcturus Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Drugs are developed using RNA interference technology platform.
|
|
| Locked | Locked | Locked |
RNAi therapeutics are developed for dermal, ophthalmic, and pulmonary diseases.
|
|
| Locked | Locked | Locked |
RNA splicing therapeutics are discovered and developed through AI-driven biotechnology.
|
|
| Locked | Locked | Locked |
Developer of drugs for anti-cancer and refractory diseases based on RNA Platform technology
|
|
| Locked | Locked | Locked |
RNAi technologies are developed for treating rare orphan diseases.
|
Detailed competitors of Orna
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Orna
Complete news archive for Orna
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Orna
Orna was founded in 2020 and raised its 1st funding round 1 year after it was founded.
Orna is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Tom Barnes is the current CEO of Orna.
Orna is a funded company, having raised a total of $201M across 2 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Orna is 113.
Orna was founded in 2020 in Cambridge, United States, within the biotechnology sector focused on RNA therapeutics. Purification methods, IRES technology for protein expression, and lipid nanoparticle formulations are developed by the company. RNA viruses and enzymes are utilized to enable production, delivery, and gene expression in the human body. Therapeutics targeting cancer, autoimmune diseases, regenerative medicine, and genetic disorders are being advanced.
Orna's top competitors include Arcturus Therapeutics, Dicerna Pharmaceuticals and OliX Pharmaceuticals.
Orna offers oRNA, panCAR, and LNP Delivery.
Orna has made 1 acquisition, including ReNAgade.
Orna has 11 investors. Key investors include Lilly, Novartis, Merck, Kite Pharma, and Bristol-Myers Squibb.